| 0.1662 0.002 (1.47%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.21  |
1-year : | 0.24 |
| Resists | First : | 0.18 |
Second : | 0.2 |
| Pivot price | 0.16 |
|||
| Supports | First : | 0.15 | Second : | 0.12 |
| MAs | MA(5) : | 0.16 |
MA(20) : | 0.17 |
| MA(100) : | 0.25 |
MA(250) : | 0.68 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.9 |
D(3) : | 21.1 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 2.54 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIM ] has closed above bottom band by 45.3%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 86 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.17 - 0.17 | 0.17 - 0.17 |
| Low: | 0.16 - 0.16 | 0.16 - 0.16 |
| Close: | 0.17 - 0.17 | 0.17 - 0.17 |
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Tue, 27 Oct 2026
Form 4 AIM ImmunoTech Inc: Thomas K. Equels (Director, CEO & President) For: 23 October - Investing.com Nigeria
Tue, 27 Oct 2026
aim immunoTech CEO Equels buys $5,068 in common stock - Investing.com
Fri, 23 Oct 2026
Aim ImmunoTech CEO Equels buys $5,093 of common stock - Investing.com
Wed, 07 Oct 2026
Exploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio. - Stock Titan
Wed, 07 Oct 2026
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays - GlobeNewswire
Thu, 01 Oct 2026
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|